PDCD1 and cancer: Research has demonstrated that cancer patients receiving ATBs concurrently with anti‐PD‐1/PD‐L1 therapy exhibited significantly worse prognosis compared to those receiving anti‐PD‐1/PD‐L1 therapy alone, while supplementation with AKK could effectively restore the efficacy of immunotherapy [116].